Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
HNMPA-AM3 -the insulin receptor tyrosine kinase inhibitor could block the anti-apoptosis effect of insulin.
胰岛素受体自身酪氨酸磷酸化抑制剂一一HNMPA一AM3可以阻断胰岛素的抗凋亡作用。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
Genistein, a natural tyrosine kinase inhibitor, has been reported to inhibit growth and induce apoptosis of various Turner cells.
金雀异黄素是一种天然的酪氨酸激酶抑制剂，可以抑制多种肿瘤细胞的增殖，并诱发细胞凋亡。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies.
本发明涉及治疗抗酪氨酸激酶抑制剂疗法的EGFR介导的疾病，特别是癌症。
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
Rigel's kinase inhibitor, called fostamatinib, targets spleen tyrosine kinase, which among other functions enables the formation of the large immune-cell complexes found in autoimmune diseases.
Rigel的激酶抑制剂，称为fostamatinib，以脾酪氨酸激酶为目标。其主要功能是可以让自身免疫疾病形成大型免疫细胞复合体。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。
CONCLUSIONS AG1109 not only was an effective inhibitor of protein tyrosine kinases, but also was a novel potent inhibitor of protein kinase CK2.
结论：AG110 9不仅是酪氨酸蛋白激酶的抑制剂，而且是一种十分有效的蛋白激酶CK2的抑制剂。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
应用推荐